Xilio Therapeutics Inc. (XLO)
0.80
-0.01 (-1.23%)
At close: Apr 23, 2025, 3:59 PM
0.82
2.29%
Pre-market: Apr 24, 2025, 04:04 AM EDT
-1.23% (1D)
| Bid | 0.79 |
| Market Cap | 41.31M |
| Revenue (ttm) | 6.34M |
| Net Income (ttm) | -58.24M |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -0.73 |
| Forward PE | -1.21 |
| Analyst | Buy |
| Ask | 0.89 |
| Volume | 83,564 |
| Avg. Volume (20D) | 3,812,547 |
| Open | 0.80 |
| Previous Close | 0.81 |
| Day's Range | 0.79 - 0.82 |
| 52-Week Range | 0.62 - 1.70 |
| Beta | -0.22 |
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2021
Employees 64
Stock Exchange NASDAQ
Ticker Symbol XLO
Website https://www.xiliotx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for XLO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 401.38% from the latest price.
Stock ForecastsNext Earnings Release
Xilio Therapeutics Inc. is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-6.2%
Xilio Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
2 months ago
+125.27%
Xilio Therapeutics shares are trading higher after the company announced an option-to-license collaboration agreement with AbbVie to develop novel tumor-activated antibody-based immunotherapies.
